OraSure Technologies, Inc.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsOraSure Technologies is a diagnostics and sample management company focused on point-of-need and home tests, including HIV, HCV, syphilis, sickle cell, and COVID-19, as well as specimen collection devices.
What they do
OraSure develops, manufactures, and sells rapid diagnostic tests and sample management solutions. Its diagnostics include tests for HIV, HCV, syphilis, sickle cell, and COVID-19, sold to labs, hospitals, clinics, and public health organizations, with some OTC consumer formats. Sample management solutions include collection devices for clinical, research, and companion animal markets, including the Colli-Pee urine collection device and microbiome products.
Revenue drivers
- Diagnostics — Core diagnostics revenues were $19.4 million in Q2 2026, up 1% year-over-year, driven by higher syphilis sales and the addition of BioMedomics' SickleSCAN test.
- Sample Management Solutions — Revenues were $9.9 million in Q2 2026, flat year-over-year, from product sales to clinical labs, research, pharmaceutical, and animal health customers.
- COVID-19 Testing — COVID-19 revenues were negligible in 2026, down 96% from prior year, reflecting the wind-down of pandemic-related demand.
- Risk Assessment Testing (discontinued) — Discontinued in Q2 2025; contributed no revenue in Q2 2026 and $1.9 million in full-year 2025.
Recent performance
Q2 2026 total net revenues were $30.6 million, down 2% year-over-year but up 9.7% sequentially, exceeding guidance. GAAP gross margin improved to 43.5% from 42.1%, and the company reported GAAP net income of $6.2 million (Diluted EPS $0.09) versus a net loss of $19.7 million in Q2 2025. For the six months ended June 30, 2026, revenues were $58.6 million, down 4%, with a net loss of $16.1 million. Full-year 2025 revenue was $115.0 million with a net loss of $68.7 million, down from 2024 revenue of $185.8 million.
Strategy
Management aims to decentralize diagnostics and focus on point-of-need and home tests, investing in innovation and strategic acquisitions. Recent steps include acquiring BioMedomics for its SickleSCAN test and submitting 510(k) applications for a rapid molecular CT/NG self-test and the Colli-Pee device. They also received FDA clearance for Colli-Pee Dx in June 2026 and EUA for OraQuick Ebola 2.0 in July 2026. The company emphasizes a strong balance sheet to fund growth and potential portfolio expansion.
Risks
- Dependence on market acceptance — Future success relies on continued adoption of oral fluid testing and collection products; if acceptance wanes, results could suffer.
- Competitive pressure — The company faces increasing competition from other diagnostic test and sample collection product providers.
- Manufacturing and scale-up challenges — Inability to manufacture products to specifications or scale up production could negatively affect revenue.
- Customer concentration — Revenue concentration in a few customers increases risk if any major customer reduces orders.
Outlook
Management stated Q2 results show continued progress in a return-to-growth trajectory, with revenue above guidance and solid gross margin improvement. They expect to leverage recent FDA clearances (Colli-Pee Dx, OraQuick Ebola 2.0) to drive growth. The company highlights a strong balance sheet with $160.6 million in cash to pursue targeted initiatives, including potential acquisitions.